Gastric Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug (Nivolumab, Pembrolizumab, Trastuzumab Deruxtecan, Trastuzumab, Ramucirumab, Zolbetuximab), By Product Type (Cytotoxic Chemotherapy, Immune Checkpoint Inhibitors), By Cancer Type (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma), By Age Group (Pediatric and Adults), By Type (Branded, Generic, Biosimilars), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration (Oral, Parenteral), By Distribution Channel (Pharmacies, Drug Stores), and Regional Forecast, 2026-2034

Last Updated: July 03, 2026 | Format: PDF | Report ID: FBI117950

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 10.55% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region
By Drug	Nivolumab Pembrolizumab Trastuzumab Deruxtecan Trastuzumab Ramucirumab Zolbetuximab Fluoropyrimidines Others
By Product Type	Cytotoxic Chemotherapy Immune Checkpoint Inhibitors HER2-Targeted Therapies VEGF/VEGFR-Targeted Therapies CLDN18.2-Targeted Therapies Nucleoside Analogue Combinations Others
By Cancer Type	Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Gastric Neuroendocrine Neoplasms Gastric Lymphoma Others
By Age Group	Pediatric Adults
By Type	Branded Generic Biosimilars
By Therapy	Targeted Therapy Immunotherapy Chemotherapy Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
By Region	North America (By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug, Product Type, Cancer Type, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa